HMG / Menotropins
Evidence: A — Established Human EvidenceHormone / Fertility
Evidence Snapshot
What this grade covers
A for MENOPUR identity, U.S. product approval, exact ART indication, label efficacy, and label safety; B for comparative ART trials; D/E for universal HMG equivalence, U.S. male-infertility approval, TRT/PCT/bodybuilding use, compounded-product equivalence, or consumer dosing.
Regulatory Context
FDA-approved menotropins products exist for specific assisted-reproductive-technology uses. Product composition, indication, route, and labeling are brand-specific and must not be inferred from a catalog entry alone.
Research Takeaway
Human menopausal gonadotropin (hMG/menotropins) is a urinary-derived gonadotropin preparation with FSH and LH biological activity; it is not a single defined peptide and is not the same product as recombinant FSH, recombinant LH, or hCG.
Evidence boundary: Shared gonadotropin biology does not make these finished products interchangeable.
See all 6 evidence claims →Quick Summary
HMG usually refers to menotropins, a purified urinary-derived gonadotropin preparation containing FSH and LH activity. It has established fertility-medicine use, while broader or male-use claims require separate evidence and regulatory context.
Mechanism & Research Overview
Menotropins are a urinary-derived gonadotropin preparation with follicle-stimulating hormone activity and luteinizing-hormone activity. They are a biological mixture, not one peptide with a single sequence.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Human menopausal gonadotropin (hMG/menotropins) is a urinary-derived gonadotropin preparation with FSH and LH biological activity; it is not a single defined peptide and is not the same product as recombinant FSH, recombinant LH, or hCG.
Does not establish
Evidence boundary: Shared gonadotropin biology does not make these finished products interchangeable.
Supported
Menopur is an FDA-approved menotropins drug for controlled ovarian stimulation in assisted reproductive technology.
Does not establish
Evidence boundary: This approval does not establish non-fertility, bodybuilding, or generalized endocrine-enhancement uses.
Supported
Randomized ART trials show that highly purified hMG can achieve pregnancy and live-birth outcomes comparable to recombinant FSH in studied controlled-ovarian-stimulation populations.
Does not establish
Evidence boundary: Comparability in specific ART trials does not establish superiority or identical outcomes across all fertility protocols.
Sources: Randomized, assessor-blinded trial comparing highly purified human menopausal gonadotropin and recombinant FSH in high responders; A randomized assessor-blind trial comparing highly purified menotropin and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer
Supported
Menotropin treatment is associated with clinically important fertility-treatment risks including ovarian hyperstimulation and multiple-pregnancy-related complications, with risk dependent on the treatment context and response.
Does not establish
Evidence boundary: This does not provide an individualized risk estimate or replace fertility-specialist monitoring.
Supported
Evidence from FDA-approved Menopur cannot be transferred automatically to unapproved products labeled HMG because biological potency, source material, purification, sterility, and formulation may differ.
Does not establish
Evidence boundary: This does not make a batch-specific claim about any named supplier.
Supported
Only named FDA-label or clinical-trial dosing may appear as Study/Trial Dosing; consumer ovarian-stimulation, male-fertility, injection, or reconstitution protocols are prohibited.
Does not establish
Evidence boundary: Published fertility protocols require individualized clinical monitoring and are not consumer instructions.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
MENOPUR labeling documents venous/arterial thrombosis, embolism, and pulmonary complications; ectopic pregnancy, spontaneous abortion, congenital malformation risk, ovarian enlargement/cyst rupture, and pregnancy as a contraindication for treatment initiation; contraindications/concerns involving sex-hormone-dependent tumors, pituitary/hypothalamic tumors, unexplained uterine bleeding, ovarian cysts of undetermined origin, uncontrolled thyroid/adrenal/pituitary disease, and primary ovarian failure; and hypersensitivity, injection-site reactions, batch/biologic variability, urinary-source impurity concerns, and lack of general interchangeability among HMG products.Safety Consideration
Menotropins can cause ovarian hyperstimulation syndrome, including serious pulmonary or vascular complications.Safety Consideration
Multiple gestation and ovarian torsion are recognized treatment risks.Safety Consideration
Catalog “HMG” does not establish the identity, purity, potency, or approval status of a specific product.
Research Areas Being Studied
Research areas discussed on this page reflect the Hormone / Fertility category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- Randomized, assessor-blinded trial comparing highly purified human menopausal gonadotropin and recombinant FSH in high responders (2020):
- A randomized assessor-blind trial comparing highly purified menotropin and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer (2012):
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Randomized, assessor-blinded trial comparing highly purified human menopausal gonadotropin and recombinant FSH in high responders | 2020 | 620 women predicted to be high responders undergoing assisted reproduction | Highly purified hMG and recombinant FSH produced broadly comparable efficacy in this selected ART population; differences in selected adverse and pregnancy outcomes were exploratory and regimen-specific. | The study does not remove established gonadotropin risks, including ovarian hyperstimulation and multiple gestation. | |
| A randomized assessor-blind trial comparing highly purified menotropin and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer | 2012 | 749 women undergoing controlled ovarian stimulation and single-blastocyst transfer | The trial compared efficacy and safety of highly purified menotropin with recombinant FSH under a defined antagonist-cycle study design. | Findings are specific to the controlled trial design and monitored ART setting. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
No Regulatory Documents & Official Trial Registries Listed Yet
This section will be updated as sources are added.
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published and official research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Published. Last updated 2026-07-30.
Follow research updates for HMG / Menotropins
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.